Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

Neutral

AI Analysis

Summary

Jazz Pharmaceuticals priced an upsized private offering of $1.1 billion in 1.875% exchangeable senior notes due 2032, with concurrent ordinary share repurchases announced.

Importance:5/10

Sentiment:

0.00

debt offeringexchangeable notesshare repurchasecapital raise

Related Companies

$JAZZ

Read the original article

Published by PR Newswire Biotech on August 27, 2026 4:30 AM

Read Original